Kindred Bio and X-BODY Announce an Exclusive Collaboration for Discovery of Antibodies for Companion Animal Health
March 31, 2014
China's Hengrui In-Licenses AMD Antibody Program from X-Body Biosciences
April 4, 2013, PharmAsia News
X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop...
Waltham, MA and Lianyungang, China, April 4, 2013, PRNewswire
X-BODY Biosciences Enters Into R&D Partnership with Tanabe Research Labs to Generate Antibody Therapeutics for Autoimmune Disorders
Waltham, MA, October 4, 2011, PRNewswire
Functional Selections for Single Domain Human VH Antibodies Against GPCR Targets Expressed on Living Cells
Discovery on Target, September 25, 2013, Boston, MA
Functional Selections for Single Domain Human VH Antibodies Against GPCR Targets Expressed on Living Cells
IBC PEGS, April 29th-30th 2013, Boston, MA

X-BODY Biosciences is a privately held biotechnology company focused on improving human health through the discovery of monoclonal antibodies against challenging membrane targets such as GPCRs and ion channels. X-BODY uses a robust DNA-encoded human naïve antibody library of remarkable diversity, cell-based functional selections, and next generation sequencing. X-BODY is pursuing human therapeutic antibodies to address a wide variety of significant diseases.